Neuro

Balt’s Squid™ Liquid Embolic Receives FDA Approval for Adjunctive Treatment for Patients with Chronic Subdural Hematomas

BOSTON, Feb. 04, 2026 (GLOBE NEWSWIRE) — Balt, Inc., a global technology leader in neurovascular devices, today announced the Premarket Approval (PMA) of the Squid™ liquid embolic agent. Squid is approved for the embolization of the middle meningeal artery (MMA) as an adjunct to usual care treatment in patients with large symptomatic chronic subdural hematoma(s) (cSDH).

Brainomix Launches Award-Winning Next Generation Stroke AI Platform with Novel Net Water Uptake Technology at the International Stroke Conference (ISC)

Brainomix 360 Stroke Next Generation has been awarded the prestigious Red Dot Design Award for excellence in usability and innovation An industry-first net water uptake feature unlocks deeper insights into stroke injury that can better inform treatment decisions New research will be…

Imperative Care Launches Zoom 4S Catheter to Further Advance Company’s Zoom Stroke System for Ischemic Stroke Treatment

A Pivotal Step in Optimizing the ADAPT 2.0 Technique for Speed and Simplicity with a Single System Setup ADAPT 2.0 with the Zoom Stroke System CAMPBELL, Calif.–(BUSINESS WIRE)–Imperative Care, Inc. today announced the commercial launch and first patient cases of the new Zoom 4S Catheter – an advanced aspiration thrombectomy […]

Pharyngeal Electrical Stimulation Recognized as Important Tool for Post-Stroke Recovery in New American Heart Association and American Stroke Association Guideline

Inclusion in new Acute Ischemic Stroke guidelines underscores clinical utility of Phagenyx for accelerating recovery from swallowing difficulties (dysphagia) in stroke patients NASHVILLE, Tenn., Jan. 27, 2026 /PRNewswire/ — Phagenesis, a commercial-stage company with a first-of-its-kind…

Ceribell Receives FDA Breakthrough Device Designation for LVO Stroke Detection and Monitoring Solution

Clearance would position the Ceribell System as the first and only point-of-care electroencephalography (EEG) technology to aid in detection and monitoring of Large Vessel Occlusion (LVO) stroke in the hospital setting Clearance would position the Ceribell System as the first and only point-of-care electroencephalography (EEG) technology to aid in detection and monitoring of Large Vessel Occlusion (LVO) stroke in the hospital setting

Hyperfine Announces FDA Clearance of the First Optive AI™ Software Update with Advanced Diffusion Imaging Capability, Focused on Enhancing Stroke Detection with the Swoop® System

A new multi-direction DWI sequence, the latest Swoop® system software, and the first advancement in Hyperfine’s Optive AI™ software, delivers clearer, higher-quality images for stroke diagnosis, enhancing the value of the Swoop® system in acute neurological care. GUILFORD, Conn.–(BUSINESS WIRE)–Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined […]

Imperative Care Presents Positive Real-World Data from Ischemic Stroke Patients Treated with ADAPT 2.0 Using the Zoom Stroke System

Late-Breaking Data Presented at Society of Vascular and Interventional Neurology Annual Meeting Demonstrated Excellent Reperfusion and Rapid Procedure Times with the Zoom Stroke System Using Large-Bore Intracranial Access, Asymmetric Aspiration, and Continuous Dual Aspiration CAMPBELL, Calif.–(BUSINESS WIRE)–Imperative Care, Inc. today announced the presentation of late-breaking, real-world data from a multi-center review […]

Spryte Medical Receives FDA IDE Approval to Initiate “INSYTE” US Pivotal Trial evaluating the nOCT Imaging System during Brain Aneurysm Treatment

BEDFORD, Mass., Nov. 19, 2025 (GLOBE NEWSWIRE) — Spryte Medical, a pioneer in intravascular neuro imaging, announced it has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to initiate the INSYTE pivotal trial. The trial will evaluate the safety and effectiveness of Spryte’s neuro Optical Coherence Tomography (nOCT) imaging system for use during intracranial aneurysm treatment procedures.

Philips and Cortechs.ai extend partnership to advance quantitative neuroimaging and strengthen Philips’ leadership in precision diagnostics in neurology

November 19, 2025Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced an extended partnership with Cortechs.ai, a pioneer in quantitative neuroimaging solutions. Together, the companies will integrate Cortechs.ai’s advanced AI-enabled neuroimaging analytics directly into Philips’ MR systems [1], empowering clinicians with faster, more objective, and reproducible insights into brain health. The collaboration strengthens Philips’ leadership in precision neuro diagnostics, combining Philips’ next-generation MR technologies with Cortechs.ai’s AI-driven quantitative neuro imaging post processing software [1] to transform how neurological diseases are detected, monitored, and managed.Combining complementary expertise for smarter brain imagingUp to 25% [2] of all MR procedures are brain scans, and radiology departments face growing demand amid increasing staff shortages. At the same time, the number of patients with neurological conditions such as Alzheimer’s disease, multiple sclerosis (MS), and brain tumors continue to rise globally. Current MR interpretation of neurodegenerative diseases or neuro oncology cases depends heavily on visual assessment, introducing variability and requiring significant expertise and time in an already overloaded system.Through this extended partnership, Philips and Cortechs.ai aim to deliver more standardized and data-driven imaging. By integrating quantitative analysis tools such as brain volumetrics, lesion quantification, and tumor tracking directly into the Philips MR imaging workflow [1], clinicians gain objective, numerical data alongside images – enabling faster, more consistent, and confident diagnoses.Empowering clinicians with precision and speedThe integration of Cortechs.ai’s NeuroQuant® solutions for Alzheimer’s, MS and brain tumors within Philips’ Smart Reading environment – a cloud-based AI platform that combines imaging, reading, and reporting directly on the MR systems [1] – marks a major step toward precision neuroimaging.With this integration, clinicians can automatically receive AI-generated quantitative reports within their standard MR workflow on the MR system or PACS, without adding extra steps for technologists. The zero-click process ensures quality-checked data and standardized outputs, helping radiologists interpret brain scans more objectively, faster and with greater confidence.“By extending our partnership with Cortechs.ai, we are accelerating the transition to fully quantitative, AI-powered neuroimaging,” said Ioannis Panagiotelis, PhD, Business Leader, MRI, Philips. “This integration brings precision, reproducibility, and efficiency to neurological MR, helping clinicians make faster, more confident decisions for patients living with complex brain conditions.”Driving productivity and improving care through AIPhilips is driving productivity and improving care through deep AI integration that tackles some of healthcare’s most pressing challenges – from workforce shortages to the growing demand for advanced diagnostics. By automatically generating quantitative reports within existing workflows, AI helps radiologists save time, improve consistency, and boost throughput. Objective numerical biomarkers enhance diagnostic accuracy, enabling more reproducible assessments and confident comparisons across time and sites. And by minimizing manual post-processing through automated, quality-controlled workflows, technologists can focus more on what matters most – delivering a better, more personalized patient experience.“Cortechs.ai’s mission has always been to empower clinicians with actionable, quantitative insights,” said Kyle Frye, Chief Executive Officer, Cortechs.ai. “By combining our advanced neuro analytics with Philips’ leading MR platform and AI infrastructure, we’re making it easier to personalize brain care and track neurological changes with precision.”Setting a new standard in precision neuro diagnosticsCortechs.ai’s  NeuroQuant® solutions are already available on Philips Advanced Visualization Workspace. With this extended partnership, Philips reinforces its commitment to advancing the field of neurology – empowering healthcare providers to deliver better care for more people, in less time, with greater confidence.